AZ3146 25 mg | 98.03%
TargetMol
AZ3146
Search Results
AZ3146 50 mg | 98.03%
TargetMol
AZ3146
Taladegib 10 mg | 98.75%
TargetMol
Taladegib is an orally bioavailable small molecule antagonist of the Hedgehog (Hh)-ligand cell surface receptor smoothened (Smo) with potential antineoplastic activity.
More Information Supplier PageTaladegib
GTS-21 dihydrochloride 5 mg | 100.00%
TargetMol
GTS-21 dihydrochloride (DMBX-anabaseine) is a nAChRs agonist. nAChRs are neuron receptor proteins that activated by the binding of the neurotransmitter ACh.
More Information Supplier PageGTS-21 dihydrochloride
GTS-21 dihydrochloride 10 mg | 100.00%
TargetMol
GTS-21 dihydrochloride (DMBX-anabaseine) is a nAChRs agonist. nAChRs are neuron receptor proteins that activated by the binding of the neurotransmitter ACh.
More Information Supplier PageGTS-21 dihydrochloride
GTS-21 dihydrochloride 100 mg | 100.00%
TargetMol
GTS-21 dihydrochloride (DMBX-anabaseine) is a nAChRs agonist. nAChRs are neuron receptor proteins that activated by the binding of the neurotransmitter ACh.
More Information Supplier PageGTS-21 dihydrochloride
TGX-221 5 mg | 98.98%
TargetMol
TGX-221, an effective, specific, and cell membrane permeable inhibitor of the PI3K p110β catalytic subunit, is utilized for cancer treatment.
More Information Supplier PageTGX-221
TGX-221 50 mg | 98.98%
TargetMol
TGX-221, an effective, specific, and cell membrane permeable inhibitor of the PI3K p110β catalytic subunit, is utilized for cancer treatment.
More Information Supplier PageTGX-221
TGX-221 10 mg | 98.98%
TargetMol
TGX-221, an effective, specific, and cell membrane permeable inhibitor of the PI3K p110β catalytic subunit, is utilized for cancer treatment.
More Information Supplier PageTGX-221
Taladegib 2 mg | 98.75%
TargetMol
Taladegib is an orally bioavailable small molecule antagonist of the Hedgehog (Hh)-ligand cell surface receptor smoothened (Smo) with potential antineoplastic activity.
More Information Supplier PageTaladegib